Literature DB >> 17526943

LOH on chromosome 11q, but not SDHD and Men1 mutations was frequently detectable in Chinese patients with pheochromocytoma and paraganglioma.

Hai-Yan Sun1, Bin Cui, Din-Wei Su, Xiao-Long Jin, Fu-Kang Sun, Yu Zu, Lei Jiang, Wei-Qing Wang, Guang Ning.   

Abstract

Recently, the succinate dehydrogenase subunit D (SDHD) gene has been reported as one of the major susceptibility genes for pheochromocytoma (PCC) and paraganglioma (PGL). In addition, loss of heterozygosity (LOH) on chromosome 11, mainly in 11q23 and 11q13, is observed frequently in PGL. Based on the fact that mutation frequency of the SDHD gene is less than that of allelic loss at chromosome11q, where the SDHD gene is located, this region may contain other candidate tumor-suppressor genes involved in pathogenesis of PCC/PGL. The tumor-suppressor gene Men1 located in 11q13 is responsible for multiple endocrine neoplasia type 1 (Men1). However, the involvement of the Men1 gene in tumorigenesis of sporadic PCC/PGL is yet to be determined. To understand the roles of the two tumor-suppressor genes and LOH on chromosome 11q in Chinese patients with sporadic PCC or PGL, we performed mutation detection of the SDHD and Men1 genes in tumors from 35 Chinese patients with PCC/PGL; we also did LOH analysis at chromosome 11q for 25 patients out of the 35. No mutation was found in all of 35 patients. However, LOH was detected at one or more loci in 11 of the 25 (44%) tumor samples. The highest frequency of LOH occurred at D11S2006 (41%). Our results suggested that mutation in SDHD or Men1 gene was not found in Chinese patients with sporadic PCC/PGL. However the loss of chromosome 11q might be critical in development of PCC or PGL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17526943     DOI: 10.1007/s12020-006-0009-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  18 in total

1.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.

Authors:  B E Baysal; R E Ferrell; J E Willett-Brozick; E C Lawrence; D Myssiorek; A Bosch; A van der Mey; P E Taschner; W S Rubinstein; E N Myers; C W Richard; C J Cornelisse; P Devilee; B Devlin
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.

Authors:  O Gimm; M Armanios; H Dziema; H P Neumann; C Eng
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 3.  Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?

Authors:  Camilo Jiménez; Gilbert Cote; Andrew Arnold; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2006-05-30       Impact factor: 5.958

4.  Active succinate dehydrogenase (SDH) and lack of SDHD mutations in sporadic paragangliomas.

Authors:  Simone Braun; Kathrin Riemann; Susan Kupka; Peter Leistenschneider; Karl Sotlar; Heide Schmid; Nikolaus Blin
Journal:  Anticancer Res       Date:  2005 Jul-Aug       Impact factor: 2.480

5.  Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas.

Authors:  Soili Kytölä; Brita Nord; Elisabeth Edström Elder; Tobias Carling; Magnus Kjellman; Björn Cedermark; Claes Juhlin; Anders Höög; Jorma Isola; Catharina Larsson
Journal:  Genes Chromosomes Cancer       Date:  2002-07       Impact factor: 5.006

Review 6.  Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1.

Authors:  S S Guo; M P Sawicki
Journal:  Mol Endocrinol       Date:  2001-10

7.  A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma.

Authors:  Alberto Cascón; Sergio Ruiz-Llorente; Sandra Rodríguez-Perales; Emiliano Honrado; Angel Martínez-Ramírez; Rocío Letón; Cristina Montero-Conde; Javier Benítez; Joaquín Dopazo; Juan C Cigudosa; Mercedes Robledo
Journal:  Genes Chromosomes Cancer       Date:  2005-03       Impact factor: 5.006

8.  Genetic testing in pheochromocytoma or functional paraganglioma.

Authors:  Laurence Amar; Jérôme Bertherat; Eric Baudin; Christiane Ajzenberg; Brigitte Bressac-de Paillerets; Olivier Chabre; Bernard Chamontin; Brigitte Delemer; Sophie Giraud; Arnaud Murat; Patricia Niccoli-Sire; Stéphane Richard; Vincent Rohmer; Jean-Louis Sadoul; Laurence Strompf; Martin Schlumberger; Xavier Bertagna; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

Review 9.  Genetics of neuroendocrine and carcinoid tumours.

Authors:  P D Leotlela; A Jauch; H Holtgreve-Grez; R V Thakker
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

10.  Chromosome 11 monosomy in conjunction with a mutated SDHD initiation codon in nonfamilial paraganglioma cases.

Authors:  Kathrin Riemann; Karl Sotlar; Susan Kupka; Simone Braun; Hans-Peter Zenner; Serena Preyer; Markus Pfister; Carsten M Pusch; Nikolaus Blin
Journal:  Cancer Genet Cytogenet       Date:  2004-04-15
View more
  5 in total

1.  A MEN1 syndrome with a paraganglioma.

Authors:  Yvan Jamilloux; Judith Favier; Morgane Pertuit; Manuela Delage-Corre; Stéphanie Lopez; Marie-Pierre Teissier; Muriel Mathonnet; Sophie Galinat; Anne Barlier; Françoise Archambeaud
Journal:  Eur J Hum Genet       Date:  2013-06-19       Impact factor: 4.246

Review 2.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes.

Authors:  B Pasini; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

3.  Somatic mutation analysis of the SDHB, SDHC, SDHD, and RET genes in the clinical assessment of sporadic and hereditary pheochromocytoma.

Authors:  Alexander Weber; Michael M Hoffmann; Hartmut P H Neumann; Zoran Erlic
Journal:  Horm Cancer       Date:  2012-05-10       Impact factor: 3.869

4.  Germline variant in REXO2 is a novel candidate gene in familial pheochromocytoma.

Authors:  Yael Laitman; Shay Tzur; Ruben Attai; Amit Tirosh; Eitan Friedman
Journal:  Genet Res (Camb)       Date:  2020-05-01       Impact factor: 1.588

5.  Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma.

Authors:  Caroline D E Margetts; Mark Morris; Dewi Astuti; Dean C Gentle; Alberto Cascon; Fiona E McRonald; Daniel Catchpoole; Mercedes Robledo; Hartmut P H Neumann; Farida Latif; Eamonn R Maher
Journal:  Endocr Relat Cancer       Date:  2008-05-22       Impact factor: 5.678

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.